Back to MW MARSHALL WACE, LLP

GALTGALT
Showing 7 of 10 quarters

Position history for MWMARSHALL WACE, LLP's holdings in GALECTIN THERAPEUTICS INC

Yes. Marshall Wace holds 831,010 shares of GALT (Galectin Therapeutics), worth $3.9M, as of its Q2 2026 13F filing. It reduced the position by 388,902 shares (-31.9%) from Q1 2026. Marshall Wace has held GALT since Q2 2025, across 5 quarterly 13F filings.

Current Value

$3.9M

Current Shares

831,010

Total Value Change

+$3.7M

Total Shares Change

+778,751

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
831,010
-31.9%
$3.9M0.0%$4.64
0
2026-Q1
Increased
1.2M
+102.6%
$3.4M0.0%$2.79
43
2025-Q4
Increased
602,134
+8.6%
$2.5M0.0%$4.16
28
2025-Q3
Increased
554,261
+1723.2%
$2.4M0.0%$4.24
42
2025-Q2
New
30,400
-
$64,1440.0%$2.11
29
2024-Q4
Exited
0
-100.0%
$00.0%$1.29
0
2024-Q3
Increased
52,259
+177.6%
$143,7120.0%$2.75
36

Other major holders of GALT: BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, OSAIC HOLDINGS, INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used